Targeting specific sugars on Ewing Sarcoma cells to improve treatment outcomes
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma
This study is testing a new treatment for Ewing sarcoma, a type of bone cancer that mostly affects kids and young adults, by using special immune cells that can better find and attack the cancer cells.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10931390 on NIH RePORTER |
What this research studies
This research investigates a new immunotherapy approach for Ewing sarcoma, a type of bone cancer that primarily affects children and young adults. The study aims to utilize chimeric antigen receptor (CAR) T cells that target a specific sugar molecule, GD2, found on the surface of cancer cells. By enhancing the effectiveness of these CAR T cells through various mechanisms, including the use of epigenetic inhibitors, the research seeks to improve the recognition and destruction of tumor cells. This innovative approach could lead to better treatment options for patients who currently have limited therapies available.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and young adults diagnosed with Ewing sarcoma, particularly those with metastatic or relapsed disease.
Not a fit: Patients with Ewing sarcoma who have already exhausted all treatment options or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment for Ewing sarcoma, potentially reducing relapse rates and improving survival outcomes.
How similar studies have performed: Other research has shown promising results using CAR T cell therapy in pediatric cancers, indicating that this approach may be effective for Ewing sarcoma as well.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Majzner, Robbie G. — Dana-Farber Cancer Inst
- Study coordinator: Majzner, Robbie G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.